Cargando…

Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Metastatic lung cancer represents a heterogeneous population of patients. Up to half of patients with metastatic lung cancer may be oligometastatic, an intermediate step between localized disease and widespread metastasis that is characterized by a limited number of metastatic deposi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Billing, David L., Rimner, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616303/ https://www.ncbi.nlm.nih.gov/pubmed/34830925 http://dx.doi.org/10.3390/cancers13225773

Ejemplares similares

Local ablative radiotherapy for oligometastatic non-small cell lung cancer
por: Suh, Yang-Gun, et al.
Publicado: (2019)

Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer
por: Santos, Patricia Mae G., et al.
Publicado: (2022)

Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy
por: Ghosn, Mario, et al.
Publicado: (2021)

Local therapy treatment conditions for oligometastatic non-small cell lung cancer
por: Zhang, Suli, et al.
Publicado: (2022)

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
por: Franceschini, Davide, et al.
Publicado: (2021)

Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review
por: Fallet, Vincent, et al.
Publicado: (2021)

Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis
por: Rim, Chai Hong, et al.
Publicado: (2023)

Radiation therapy for oligometastatic oropharyngeal cancer
por: Martini, Stefania, et al.
Publicado: (2020)

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021)

Successful continuous nivolumab therapy for metastatic non‐small cell lung cancer after local treatment of oligometastatic lesions
por: Tobita, Satoshi, et al.
Publicado: (2020)

Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis
por: Zhang, Chenxi, et al.
Publicado: (2021)

Radiation therapy for oligometastatic bone disease in breast cancer
por: Katayama, Norihisa, et al.
Publicado: (2020)

Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer—a two center experience
por: Mantel, Frederick, et al.
Publicado: (2021)

Classifying Oligometastatic Non-Small Cell Lung Cancer
por: Blumenthaler, Alisa N., et al.
Publicado: (2021)

Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer
por: Werner, Raphael S., et al.
Publicado: (2021)

Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020)

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
por: Bai, Hao, et al.
Publicado: (2016)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results
por: Reyngold, Marsha, et al.
Publicado: (2019)

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update
por: Chen, Yi-Hsing, et al.
Publicado: (2022)

Oligometastatic non-small cell lung cancer: Current management
por: Román-Jobacho, Alicia, et al.
Publicado: (2021)

The Role of Surgery for Oligometastatic Non-Small Cell Lung Cancer
por: Euhus, Caleb J., et al.
Publicado: (2022)

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
por: Hu, Xiaolong, et al.
Publicado: (2022)

Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

The changing role of radiation therapy in the management of oligometastatic disease
por: Tharmalingham, H., et al.
Publicado: (2017)

Radiation-Induced Dyspnea in Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy
por: Cella, Laura, et al.
Publicado: (2021)

Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer
por: Jones, Gregory D., et al.
Publicado: (2021)

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study
por: Chen, Ya, et al.
Publicado: (2022)

Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
por: Wu, Han, et al.
Publicado: (2022)

The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
por: Dahele, Max, et al.
Publicado: (2011)

Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial
por: Tibdewal, Anil, et al.
Publicado: (2021)

Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors
por: Sulaiman, Nor Shazrina, et al.
Publicado: (2014)

Oligometastatic non-small-cell lung cancer: current treatment strategies
por: Richard, Patrick J, et al.
Publicado: (2016)

Current treatment landscape for oligometastatic non-small cell lung cancer
por: Garde-Noguera, Javier, et al.
Publicado: (2022)

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience
por: Deek, Matthew P., et al.
Publicado: (2019)

Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study
por: Gomez, Daniel R., et al.
Publicado: (2016)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type
por: Hu, Xiaolong, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
por: Dhaliwal, Inderdeep, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6qpg5ipco6gtfeogef9vp1cl7c